Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Medtronic
Baxter
Colorcon
Boehringer Ingelheim

Last Updated: January 27, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for MT-1303


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug MT-1303?

MT-1303 is an investigational drug.

There have been 12 clinical trials for MT-1303. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.

The most common disease conditions in clinical trials are Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, and Crohn Disease. The leading clinical trial sponsors are Mitsubishi Tanabe Pharma Corporation, Bausch Health Americas, Inc., and [disabled in preview].

There are two US patents protecting this investigational drug and thirty international patents.

Recent Clinical Trials for MT-1303
TitleSponsorPhase
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative ColitisBausch Health Americas, Inc.Phase 2
Extension Study of MT-1303 in Subjects With Crohn's DiseaseMitsubishi Tanabe Pharma CorporationPhase 2
Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's DiseaseMitsubishi Tanabe Pharma CorporationPhase 2

See all MT-1303 clinical trials

Clinical Trial Summary for MT-1303

Top disease conditions for MT-1303
Top clinical trial sponsors for MT-1303

See all MT-1303 clinical trials

US Patents for MT-1303

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MT-1303 ⤷  Try it Free 4-alkoxy-3-(trifluoromethyl)benzyl alcohol production method MITSUBISHI TANABE PHARMA CORPORATION (Osaka-Shi, JP) ⤷  Try it Free
MT-1303 ⤷  Try it Free Amine compound and use thereof for medical purposes Mitsubishi Tanabe Pharma Corporation (Osaka-shi, JP) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MT-1303

Drugname Country Document Number Estimated Expiration Related US Patent
MT-1303 European Patent Office EP3492448 2036-07-29 ⤷  Try it Free
MT-1303 European Patent Office EP3819285 2036-07-29 ⤷  Try it Free
MT-1303 Spain ES2862949 2036-07-29 ⤷  Try it Free
MT-1303 Japan JP6961595 2036-07-29 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Medtronic
Baxter
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.